两种小剂量利妥昔单抗治疗方案治疗原发免疫性血小板减少症疗效比较  

Efficacy and safety of two different low-dose rituximab regimens for Chinese adult patients with immune thrombocytopenia

作　　者：隋涛[2] 张磊[1] 周泽平 薛峰 葛菁 杨仁池 

机构地区：[1]中国医学科学院、北京协和医学院血液学研究所、血液病医院,天津300020 [2]天津市第一中心医院血液科,300092

出　　处：《中华血液学杂志》2011年第9期583-586,共4页Chinese Journal of Hematology

基　　金：国家自然科学基金（30670900,81070397）;公益性卫生行业科研专项基金（200802031）

摘　　要：目的比较两种小剂量利妥昔单抗治疗方案治疗成人原发免疫性血小板减少症（ITP）的疗效。方法51例ITP患者非随机分为两组：A组31例患者利妥昔单抗用量为100mg／周，连续4周；B组20例患者利妥昔单抗用量为375mg／m^2，只用1次。结果A组：总有效（OR）率和完全反应（CR）率分别为58％和29％，中位反应时间为42（10～101）d。中位随访时间为15（10～16）个月。3例患者复发。B组：0R和cR率分别为50％和35％，中位反应时间为35（18～108）d。中位随访时间为13（6～17）个月，1例患者复发。两组患者中0R、cR及无复发生存（RFS）率差异无统计学意义（P值均〉0．05）。结论两种小剂量利妥昔单抗治疗方案治疗成人ITP疗效没有差异，小剂量利妥昔单抗可作为慢性ITP治疗的选择。Objective To compare the efficacy of two different regimens of low doses rituximab for the treatment of adult patients with immune thrombocytopenia（ITP）. Methods Fifty-one patients were enrolled in this study and was non-randomly assigned to receive 100 mg rituximab weekly for 4 weeks （group A, 31 cases） or a single dose of 375 mg/m2 rituximab （group B, 20 cases）. Results For group A： Overall and complete response（OR and CR） rates were 58% and 29% , respectively. In responders, the median time to response was 42 （ 10 - 101 ） days, with a median follow-up time of 15（ 10 - 16） months, 3 of 18 responders （ 17% ） relapsed. For group B ： OR and CR rates were 50% and 35% , respectively. In responders, the median time to response was 35 （18 -108） days, with a median follow-up time of 13 （6 -17） months, 1 of 9 responders （ 11% ） relapsed. No significant difference in the OR, CR, the relapse rate and relapse free survival was obsePeed in patients between the two groups. Conclusion The low dose rituximab regimen（ 100 mg weekly for 4 weeks or a single close of 375 mg/m^2 ） may be a useful alternative therapy in patients with ITP.

关 键 词：血小板减少 抗体 CD20 剂量效应关系 药物 治疗结果 

分 类 号：R558.2[医药卫生—血液循环系统疾病]